A Capsid Virus-like Particle Based Vaccine Displaying IL-11 for Treatment of Fibrotic Diseases
Time: 11:00 am
day: Conference Day Two
Details:
- Leveraging AdaptVac’s virus-like particles-based vaccine platform with proven safety in clinical trials, to display self-antigens for the induction of autoreactive antibodies for the treatment of chronic diseases.
- Showing proof of mechanism for an IL11 targeting vaccine in overcoming immune tolerance in mice and guinea pigs
- Demonstrating proof of concept in a MASH guinea pig model, validating translational relevance for targeting IL11 in MASH patients and positioning cVLP-IL-11 as a firstin- class immunotherapy for metabolic fibrosis.
